LegoChem’s $1.2bn ADC Platform Deal With Amgen Signals Continued Big Pharma Interest
Fourth ADC Platform License Deal For LCB
LegoChem’s hefty out-licensing deal with Amgen seems to further prove global pharma’s keen interest in the Korean ADC leader’s technology, said to be differentiated with safer margins.
